D. Boral Capital Reiterates "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX)

D. Boral Capital reiterated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Stock Down 2.7 %

Shares of ANIX traded down $0.06 during midday trading on Tuesday, hitting $2.13. The company's stock had a trading volume of 126,738 shares, compared to its average volume of 77,717. Anixa Biosciences has a one year low of $2.07 and a one year high of $5.13. The stock has a market capitalization of $68.54 million, a price-to-earnings ratio of -5.46 and a beta of 0.90. The company's fifty day simple moving average is $2.89 and its two-hundred day simple moving average is $3.03.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, research analysts predict that Anixa Biosciences will post -0.42 earnings per share for the current year.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC boosted its position in shares of Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company's stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the third quarter worth $34,000. Westside Investment Management Inc. boosted its position in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock valued at $110,000 after acquiring an additional 21,100 shares in the last quarter. Concorde Asset Management LLC bought a new stake in Anixa Biosciences during the second quarter worth about $31,000. Finally, Tyler Stone Wealth Management increased its position in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company's stock valued at $132,000 after buying an additional 21,008 shares in the last quarter. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.